The U.S. Food and Drug Administration (FDA) has issued a safety communication regarding glatiramer acetate, a medication used to treat relapsing forms of multiple sclerosis (MS). The FDA has added a Boxed Warning to the drug’s prescribing information, cautioning users about a rare but potentially fatal allergic reaction called anaphylaxis, which can occur at any point during treatment.
Continues after this brief message…
Did you know? Paid supporters get a reduced ad experience!
We know you value local news and entertainment that is free, open, and independent. Producing high-quality, paywall-free content isn't free. It takes time, effort, and resources to keep you informed and entertained. Unlike corporate media, we don’t have deep-pocketed investors or big advertisers funding our work—we rely on you, our readers and listeners, to keep Radio Free Hub City running. We're literally running on a shoe-string budget, but keep working hard to provide as much news and entertainment as we can.
If just 5% of local area residents became paid supporters at only $5 per month, we could meet our fundraising goals and continue expanding our news coverage depth while continuing to provide free access for everyone. So, if you'd like to help us in our continuing quest to improve our coverage, please consider becoming a paying supporter.
Will you be one of the 5%?
Thank you for supporting Radio Free Hub City!
Glatiramer acetate, marketed under the brand names Copaxone and Glatopa, is an injectable medication available in daily or thrice-weekly dosing schedules. Although immediate post-injection reactions—such as flushing, chest pain, or hives—are relatively common and self-resolving, anaphylaxis is rare, more severe, and requires urgent medical intervention. Symptoms of anaphylaxis, including wheezing, facial swelling, or difficulty breathing, typically appear within an hour of injection and may rapidly escalate.
Patients and caregivers are advised to seek emergency medical assistance if symptoms persist, worsen, or do not resolve promptly. The FDA has also warned that anaphylaxis can occur months or even years after initiating treatment. Those who experience this reaction should not resume the medication without identifying an alternative cause.
Article continues after these messages…
While other outlets focus on getting quotes from politicians who don't even live in our congressional district, we're focused on providing the hard-hitting truths and facts without political spin. We don't lock our news behind a paywall, will you help us keep it that way? If you're tired of news sweetened with confirmation bias, consider becoming a monthly supporter. But if you're not, that's fine too—we're confident in our mission and will be here if you decide you're ready for the truth. Just $5/month helps fund our local reporting, live election night coverage, and more.
Become a paid supporter for reduced ad experience!
Healthcare professionals are urged to educate patients about the differences between immediate post-injection reactions and anaphylaxis, emphasizing the need for prompt action if severe symptoms develop. The FDA further advises against restarting the medication in patients with a history of anaphylaxis related to glatiramer acetate unless another clear cause is determined.
This new safety measure underscores the importance of vigilance in monitoring potential adverse reactions to glatiramer acetate. Patients with concerns are encouraged to consult their healthcare providers.
Article by multiple RFHC contributors.
Do you believe we got something wrong? Please read our publishing standards and corrections policy.
Did you know? Supporters get a reduced ad experience!
Sponsored Articles
Get daily and breaking news for Washington County, MD area from Radio Free Hub City. Sign up with your email today!
Paid supporters have a reduced ad experience!
Discover more from Radio Free Hub City
Subscribe to get the latest posts sent to your email.